Table 2.
Nonstandardised results.
| Control group (n = 42) |
T2DM group (n = 42) |
p | |
|---|---|---|---|
| Serum | |||
| SAA (mg/L)∗ | 15 (7, 36) | 30 (17, 68) | 0.002 |
| PON-1 (U/L) | 41,109 (5690) | 38,245 (7025) | 0.043 |
| HDL2 | |||
| ApoA1 (mg/L)∗ | 167.0 (151.0, 190.9) | 162.9 (151.0, 170.3) | 0.443 |
| SAA (mg/L)∗ | 0.4 (0.2, 0.7) | 1.0 (0.6, 2.2) | <0.001 |
| PON-1 (U/L)∗ | 293.8 (189.4, 471.5) | 331.1 (216.2, 466.7) | 0.378 |
| CETP (μmol/L) | 217.1 (25.1) | 232.6 (14.1) | 0.001 |
| LCAT (ratio 470/390) | 0.974 (0.049) | 0.977 (0.046) | 0.809 |
| HDL3 | |||
| ApoA1 (mg/L) | 1908 (251.2) | 1926 (178.1) | 0.704 |
| SAA (μg/L)∗ | 6 (3, 13) | 13 (8, 29) | <0.001 |
| PON-1 (U/L) | 9656 (4003) | 10,551 (2087) | 0.203 |
| CETP (μmol/L) | 245.2 (41.2) | 279.5 (17.7) | <0.001 |
| LCAT (ratio 470/390) | 0.945 (0.051) | 0.948 (0.047) | 0.833 |
Results expressed as mean (SD) or as geometric mean (interquartile range) if not normally distributed, where ∗ indicates skewed distributions.